Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) report

To evaluate the impact of a microscopically positive resection margin (microPRM) on the outcome of hepatoblastoma patients pretreated with chemotherapy. Local recurrence and survival rates of 431 children treated in the SIOPEL 2 and 3 trials were analysed comparing 58 patients with microPRM with 371...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2019-01, Vol.106, p.126-132
Hauptverfasser:	Aronson, Daniel C., Weeda, Víola B., Maibach, Rudolf, Czauderna, Piotr, Dall’Igna, Patrizia, de Ville de Goyet, Jean, Branchereau, Sophie, Perilongo, Giorgio, Brock, Penelope, Zsiros, Joszef, Semeraro, Michaela, Chardot, Christophe, Wildhaber, Barbara, Morland, Bruce, Brugières, Laurence
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Factors Chemotherapy Chemotherapy, Adjuvant Child Child, Preschool Children Cisplatin Clinical trials Clinical Trials as Topic Confidence intervals Europe Female Health risks Hepatectomy - adverse effects Hepatectomy - mortality Hepatoblastoma Hepatoblastoma - mortality Hepatoblastoma - pathology Hepatoblastoma - surgery Humans Infant Infant, Newborn Liver Liver cancer Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Male Margins of Excision Medical prognosis Neoadjuvant Therapy Neoplasm Recurrence, Local Neoplasm, Residual Outcome Partial liver resection Patients Positive margin Progression-Free Survival Risk Risk Assessment Risk Factors Risk groups Surgery Survival Time Factors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To evaluate the impact of a microscopically positive resection margin (microPRM) on the outcome of hepatoblastoma patients pretreated with chemotherapy. Local recurrence and survival rates of 431 children treated in the SIOPEL 2 and 3 trials were analysed comparing 58 patients with microPRM with 371 who had a complete resection (CR) and who were then stratified by risk category. The tumour was standard-risk in 312 patients and high-risk (PRETEXT IV and/or extrahepatic disease and/or α-fetoprotein [AFP]
ISSN:	0959-8049 1879-0852
DOI:	10.1016/j.ejca.2018.10.013